Gilead Sciences and the World Health Organization (WHO) are doubling down on a pact to eliminate deadly parasitic disea | Gilead’s five-year contract with the WHO is centered on providing AmBisome to countries that make up 74% of the global visceral leishmaniasis burden, according to the company.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Gilead will donate vials of its antifungal medication AmBisome to help global efforts in eliminating visceral leishmaniasis.
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic…
Eli Lilly has doubled down on its partnership with CDMO Resilience as the companies embark on a $750 million investment to…
A combination of Merck’s islatravir and Gilead’s lenacapavir has
A phase 3 study of Gilead’s Livdelzi has met its primary endpoint,
Eli Lilly has made a six-year, $50 m | Eli Lilly has made a six-year, $50 million commitment to UNICEF USA to support efforts to…
